Are There Any Criticisms of TRIPS in the Context of Cancer?
While TRIPS aims to create a uniform standard for IP protection, it has faced criticism for potentially limiting access to essential medicines. Critics argue that the agreement can prioritize the profits of pharmaceutical companies over the health needs of patients, particularly in developing countries. The high cost of patented cancer drugs can make them inaccessible to many who need them, prompting calls for reform and the use of TRIPS flexibilities to enhance access to life-saving medications.
